Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Albutein 5% Clear all
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

NCT02332889
View directory record Official record
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT01376778
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions
CMV hyperimmune globulin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 19, 2026, 2:54 PM EDT
Withdrawn Phase 2 Interventional

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

NCT01035593
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
plasmapheresis and IVIG, recombinant C1 inhibitor
Procedure · Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

NCT00824005
View directory record Official record
Conditions
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 19, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional Results available

Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients

NCT02654782
View directory record Official record
Conditions
Hemodynamic Stability
Interventions
Lactated Ringer's, 5% Human Albumin
Drug
Lead sponsor
William C. Oliver
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 19, 2026, 2:54 PM EDT
Terminated Phase 1 Interventional

A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients

NCT03950414
View directory record Official record
Conditions
Cytomegalovirus Infections, Solid Organ Transplant
Interventions
CMV specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

NCT00199862
View directory record Official record
Conditions
Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor, COlorectal Carcinoma
Interventions
Iodine-124 labeled humanized A33 (antibody)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 19, 2026, 2:54 PM EDT
Terminated Phase 3 Interventional Results available

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure
Interventions
SMT + PE-A 5%, Standard Medical Treatment
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

NCT02872142
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Albutein 5%, Plasma Exchange
Biological · Procedure
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
19 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 19, 2026, 2:54 PM EDT
Withdrawn Not applicable Interventional

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

NCT02061605
View directory record Official record
Conditions
Benign Renal Tumors, Malignant Renal Tumors
Interventions
Laser Tissue Welding Device
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 19, 2026, 2:54 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

NCT06534450
View directory record Official record
Conditions
Aging
Interventions
Sham, Therapeutic Plasma Exchange, IVIG
Device · Drug
Lead sponsor
Dobri Kiprov
Industry
Eligibility
50 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Mill Valley, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

NCT01843894
View directory record Official record
Conditions
Dry Eye
Interventions
RU-101
Biological
Lead sponsor
R-Tech Ueno, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

NCT00666263
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 2:54 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

NCT02613052
View directory record Official record
Conditions
Transesophageal Echocardiography Contrast Agents
Interventions
normal saline, human albumin, human albumin and propofol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT00220740
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

NCT02192502
View directory record Official record
Conditions
Postoperative Kidney Injury
Interventions
human albumin 5%, HES 130/0.4 (Voluven)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 85 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years to 70 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 19, 2026, 2:54 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT07408583
View directory record Official record
Conditions
Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure Disorders, Genetic Diseases, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders, Cancer Predisposition Syndrome
Interventions
IUHSCT for FA-affected fetuses
Biological
Lead sponsor
Agnieszka Czechowicz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2033
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 19, 2026, 2:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 19, 2026, 2:54 PM EDT
Terminated Phase 3 Interventional Results available

Albumin in Acute Ischemic Stroke Trial

NCT00235495
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 83 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 19, 2026, 2:54 PM EDT